Coming Next Week: Updates on MBTG, NWCI and More

Next week, we will feature a special follow-up report on Millennium Biotechnologies Group Inc. (MBTG.OB), which was the subject of a trade alert earlier this week.

Also next week, we'll have an update on NewCardio, Inc. (NWCI.OB). This is a company we've been watching closely in anticipation of a partnership development and our sources tell us that the company may have additional news regarding revenue generating contracts in the coming days.  NewCardio, Inc., a development-stage cardiac diagnostic company, focuses on the research, development, and commercialization of proprietary software platform technology solutions for the non-invasive diagnosis and monitoring of cardiovascular disease, as well as for the cardiac safety assessment of drugs under development. The company’s technology platform provides real-time and 3-D analysis of the heart's electrical activity as detected at the body surface by standard 12-lead electrocardiogram(ECG) electrodes. Its developing products include QTinno, a phase I trial product, which is an automated cardiac safety solution that replaces the manual and/or semi-automated methodologies with algorithms that automatically measure, analyze, and report on the ECGs collected; and CardioBip, a mobile ECG transtelephonic system comprising a mobile ECG recording and transmitting device, and a diagnostic center that receives, processes, and analyzes the data.

Finally, we will be spotlighting a company with an FDA approved imaging technology on the verge of some big news that is trading at a share prices far less expensive than other penny stock competitiors like Imaging3 Inc. (IMGG.OB), who still don't have FDA approval.

Stay tuned for these reports and more coming next week on BioMedReports.Com.

BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read in the About Us Section

---

Add this page to your favorite Social Bookmarking websites